Sorafenib induces autophagy and suppresses activation of human macrophage

Jiunn Chang Lin, Chien Liang Liu, Jie Jen Lee, Tsan Pai Liu, Wen Chin Ko, Yu Chuen Huang, Chih Hsiung Wu, Yu Jen Chen

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background Sorafenib, a multi-kinase inhibitor approved for treatment of advanced renal cell carcinoma and other malignancies, has been shown as a modulator for dendritic cells. This study was designed to examine the effects of sorafenib on macrophages, the major ontogeny of innate immunity. Materials and methods Macrophages were derived from sorted CD14+ monocytes of human peripheral blood mononuclear cells. Cell viability and surface antigens were examined by trypan blue analysis. Autophagy was characterized by light microscopy and transmission electron microscopy for morphology, Western blotting for microtubule associated light chain protein 3B (LC-3B) I lipidation, and acridine orange staining for acidic component vacuoles. Soluble factors contained in culture medium and serum were measured by ELISA. Results We found that sorafenib inhibited the viability of macrophages accompanied by morphological changes characteristic of autophagy. This autophagy-inducing effect was validated by LC3B-I lipidation and autophagosome accumulation. The surface antigen expression and the function of activated macrophages were inhibited by sorafenib, including the expression of co-stimulatory molecule CD80, phagocytosis, and the production of reactive oxygen species. The secretion of IL-10, but not IL-6, TNF-α nor TGF-β, was reduced by sorafenib. Conclusion Sorafenib, in addition to being a cancer targeted therapeutic agent, can induce autophagy and modulate the function of human macrophages.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalInternational Immunopharmacology
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Macrophage Activation
Autophagy
Macrophages
Surface Antigens
Light
Acridine Orange
Trypan Blue
Vacuoles
Transmission Electron Microscopy
Phagocytosis
Renal Cell Carcinoma
Innate Immunity
Microtubules
Interleukin-10
Dendritic Cells
Culture Media
sorafenib
Monocytes
Microscopy
Interleukin-6

Keywords

  • Autophagy
  • Macrophage
  • Sorafenib

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Lin, J. C., Liu, C. L., Lee, J. J., Liu, T. P., Ko, W. C., Huang, Y. C., ... Chen, Y. J. (2013). Sorafenib induces autophagy and suppresses activation of human macrophage. International Immunopharmacology, 15(2), 333-339. https://doi.org/10.1016/j.intimp.2013.01.006

Sorafenib induces autophagy and suppresses activation of human macrophage. / Lin, Jiunn Chang; Liu, Chien Liang; Lee, Jie Jen; Liu, Tsan Pai; Ko, Wen Chin; Huang, Yu Chuen; Wu, Chih Hsiung; Chen, Yu Jen.

In: International Immunopharmacology, Vol. 15, No. 2, 02.2013, p. 333-339.

Research output: Contribution to journalArticle

Lin, JC, Liu, CL, Lee, JJ, Liu, TP, Ko, WC, Huang, YC, Wu, CH & Chen, YJ 2013, 'Sorafenib induces autophagy and suppresses activation of human macrophage', International Immunopharmacology, vol. 15, no. 2, pp. 333-339. https://doi.org/10.1016/j.intimp.2013.01.006
Lin, Jiunn Chang ; Liu, Chien Liang ; Lee, Jie Jen ; Liu, Tsan Pai ; Ko, Wen Chin ; Huang, Yu Chuen ; Wu, Chih Hsiung ; Chen, Yu Jen. / Sorafenib induces autophagy and suppresses activation of human macrophage. In: International Immunopharmacology. 2013 ; Vol. 15, No. 2. pp. 333-339.
@article{1cb57d46a8fd4323a98e7676a3f858a4,
title = "Sorafenib induces autophagy and suppresses activation of human macrophage",
abstract = "Background Sorafenib, a multi-kinase inhibitor approved for treatment of advanced renal cell carcinoma and other malignancies, has been shown as a modulator for dendritic cells. This study was designed to examine the effects of sorafenib on macrophages, the major ontogeny of innate immunity. Materials and methods Macrophages were derived from sorted CD14+ monocytes of human peripheral blood mononuclear cells. Cell viability and surface antigens were examined by trypan blue analysis. Autophagy was characterized by light microscopy and transmission electron microscopy for morphology, Western blotting for microtubule associated light chain protein 3B (LC-3B) I lipidation, and acridine orange staining for acidic component vacuoles. Soluble factors contained in culture medium and serum were measured by ELISA. Results We found that sorafenib inhibited the viability of macrophages accompanied by morphological changes characteristic of autophagy. This autophagy-inducing effect was validated by LC3B-I lipidation and autophagosome accumulation. The surface antigen expression and the function of activated macrophages were inhibited by sorafenib, including the expression of co-stimulatory molecule CD80, phagocytosis, and the production of reactive oxygen species. The secretion of IL-10, but not IL-6, TNF-α nor TGF-β, was reduced by sorafenib. Conclusion Sorafenib, in addition to being a cancer targeted therapeutic agent, can induce autophagy and modulate the function of human macrophages.",
keywords = "Autophagy, Macrophage, Sorafenib",
author = "Lin, {Jiunn Chang} and Liu, {Chien Liang} and Lee, {Jie Jen} and Liu, {Tsan Pai} and Ko, {Wen Chin} and Huang, {Yu Chuen} and Wu, {Chih Hsiung} and Chen, {Yu Jen}",
year = "2013",
month = "2",
doi = "10.1016/j.intimp.2013.01.006",
language = "English",
volume = "15",
pages = "333--339",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Sorafenib induces autophagy and suppresses activation of human macrophage

AU - Lin, Jiunn Chang

AU - Liu, Chien Liang

AU - Lee, Jie Jen

AU - Liu, Tsan Pai

AU - Ko, Wen Chin

AU - Huang, Yu Chuen

AU - Wu, Chih Hsiung

AU - Chen, Yu Jen

PY - 2013/2

Y1 - 2013/2

N2 - Background Sorafenib, a multi-kinase inhibitor approved for treatment of advanced renal cell carcinoma and other malignancies, has been shown as a modulator for dendritic cells. This study was designed to examine the effects of sorafenib on macrophages, the major ontogeny of innate immunity. Materials and methods Macrophages were derived from sorted CD14+ monocytes of human peripheral blood mononuclear cells. Cell viability and surface antigens were examined by trypan blue analysis. Autophagy was characterized by light microscopy and transmission electron microscopy for morphology, Western blotting for microtubule associated light chain protein 3B (LC-3B) I lipidation, and acridine orange staining for acidic component vacuoles. Soluble factors contained in culture medium and serum were measured by ELISA. Results We found that sorafenib inhibited the viability of macrophages accompanied by morphological changes characteristic of autophagy. This autophagy-inducing effect was validated by LC3B-I lipidation and autophagosome accumulation. The surface antigen expression and the function of activated macrophages were inhibited by sorafenib, including the expression of co-stimulatory molecule CD80, phagocytosis, and the production of reactive oxygen species. The secretion of IL-10, but not IL-6, TNF-α nor TGF-β, was reduced by sorafenib. Conclusion Sorafenib, in addition to being a cancer targeted therapeutic agent, can induce autophagy and modulate the function of human macrophages.

AB - Background Sorafenib, a multi-kinase inhibitor approved for treatment of advanced renal cell carcinoma and other malignancies, has been shown as a modulator for dendritic cells. This study was designed to examine the effects of sorafenib on macrophages, the major ontogeny of innate immunity. Materials and methods Macrophages were derived from sorted CD14+ monocytes of human peripheral blood mononuclear cells. Cell viability and surface antigens were examined by trypan blue analysis. Autophagy was characterized by light microscopy and transmission electron microscopy for morphology, Western blotting for microtubule associated light chain protein 3B (LC-3B) I lipidation, and acridine orange staining for acidic component vacuoles. Soluble factors contained in culture medium and serum were measured by ELISA. Results We found that sorafenib inhibited the viability of macrophages accompanied by morphological changes characteristic of autophagy. This autophagy-inducing effect was validated by LC3B-I lipidation and autophagosome accumulation. The surface antigen expression and the function of activated macrophages were inhibited by sorafenib, including the expression of co-stimulatory molecule CD80, phagocytosis, and the production of reactive oxygen species. The secretion of IL-10, but not IL-6, TNF-α nor TGF-β, was reduced by sorafenib. Conclusion Sorafenib, in addition to being a cancer targeted therapeutic agent, can induce autophagy and modulate the function of human macrophages.

KW - Autophagy

KW - Macrophage

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84873047792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873047792&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2013.01.006

DO - 10.1016/j.intimp.2013.01.006

M3 - Article

C2 - 23337882

AN - SCOPUS:84873047792

VL - 15

SP - 333

EP - 339

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -